STE STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1757898 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.1%
TTM net income YoY20.1%
TTM EPS YoY21.7%
Revenue 3-yr CAGR8.6%
Net income 3-yr CAGR14.6%
Margins
Gross margin44.6%
Operating margin19.0%
Net margin13.4%
FCF margin15.2%
EBITDA margin27.0%
Returns
ROE11.6%
ROA7.8%
ROIC (approx.)10.0%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.26x
Current ratio2.05x
Interest coverage20.53x
Cash quality & payout
Operating cash flow / net income1.56x
Accruals ratio-4.4%
Payout ratio30.5%
Capex / revenue5.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B |
| Cost of revenue | $3.31B | $3.06B | $2.92B | $2.56B | $2.34B |
| Gross profit | $2.63B | $2.40B | $2.22B | $1.98B | $1.88B |
| R&D expense | $112.90M | $107.60M | $103.70M | $98.48M | $86.66M |
| SG&A expense | $1.41B | $1.33B | $1.25B | $1.09B | $1.32B |
| Operating income | $1.10B | $866.60M | $836.10M | $791.10M | $477.81M |
| Interest expense | $60.70M | $86.30M | $144.40M | $107.96M | $89.49M |
| Pretax income | $1.05B | $796.20M | $702.80M | $680.27M | $366.80M |
| Income tax | $262.20M | $184.70M | $149.50M | $124.07M | $82.34M |
| Net income | $782.30M | $614.60M | $378.20M | $107.03M | $243.89M |
| EBITDA | $1.59B | $1.34B | $1.40B | $1.34B | $1.03B |
| EPS (basic) | 7.97 | 6.24 | 3.83 | 1.07 | 2.50 |
| EPS (diluted) | 7.93 | 6.20 | 3.81 | 1.07 | 2.48 |
| Dividends declared per share | 2.46 | 2.23 | 2.03 | 1.84 | 1.69 |
| Weighted avg. shares (diluted) | 98.70M | 99.10M | 99.40M | 100.25M | 98.33M |
| Balance sheet | |||||
| Cash & equivalents | $439.60M | $171.70M | $207.00M | $208.40M | $348.32M |
| Receivables | $1.09B | $1.04B | $1.01B | $864.99M | $799.04M |
| Inventory | $631.80M | $581.30M | $674.53M | $604.41M | $575.00M |
| Current assets | $2.39B | $2.00B | $2.87B | $2.01B | $1.88B |
| PP&E, net | $2.16B | $1.96B | $1.77B | $1.63B | $1.55B |
| Goodwill | $4.19B | $4.10B | $4.07B | $3.88B | $3.94B |
| Intangibles | $1.62B | $1.85B | $2.12B | $2.08B | $3.33B |
| Total assets | $10.74B | $10.15B | $11.06B | $10.82B | $11.42B |
| Current liabilities | $1.15B | $1.02B | $931.13M | $861.84M | $922.22M |
| Short-term debt | $118.90M | $125.00M | $85.94M | $60.00M | $142.88M |
| Long-term debt | $1.81B | $1.92B | $3.12B | $3.02B | $2.95B |
| Total debt | $1.93B | $2.04B | $3.21B | $3.08B | $3.09B |
| Total liabilities | $3.54B | $3.53B | $4.75B | $4.73B | $4.88B |
| Shareholders' equity | $7.18B | $6.60B | $6.30B | $6.08B | $6.53B |
| Net debt | $1.49B | $1.87B | $3.00B | $2.87B | $2.74B |
| Shares outstanding | 97.80M | 98.30M | 98.88M | 98.63M | 100.07M |
| Cash flow statement | |||||
| Operating cash flow | $1.34B | $1.15B | $973.30M | $756.95M | $684.81M |
| Capital expenditure | $369.00M | $370.10M | $360.30M | $361.97M | $287.56M |
| Free cash flow | $972.40M | $778.00M | $613.00M | $394.98M | $397.25M |
| Investing cash flow | -$512.50M | $388.80M | -$887.40M | -$383.33M | -$666.56M |
| Financing cash flow | -$568.20M | -$1.57B | -$85.20M | -$498.72M | $115.83M |
| Depreciation & amortization | $486.50M | $476.20M | $565.20M | $552.90M | $553.10M |
| Stock-based compensation | $61.70M | $57.40M | $56.50M | $38.95M | $57.66M |
| Dividends paid | $241.80M | $219.90M | $200.60M | $183.50M | $163.17M |
| Share buybacks | $235.50M | $211.30M | $11.80M | $308.56M | $55.78M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.